How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,131 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy

outpatients with FN do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen, should they be considered for hospitalization or continue to be treated on an outpatient basis? METHODS Section: Guideline Update Development Process This systematic review–based guideline product was developed by an Expert Panel with multidisciplinary expertise (Appendix , online only). A patient representative and an ASCO guidelines staff member with health research methodology experience (...) , including frequent clinic visits ○Family member or caregiver at home 24 h/d ○Access to a telephone and transportation 24 h/d ○No history of noncompliance with treatment protocols •The following additional measures are recommended: ○Frequent evaluation for at least 3 days in clinic or at home ○Daily or frequent telephone contact to verify (by home thermometry) that fever resolves ○Monitoring of ANC and platelet count for myeloid reconstitution ○Frequent return visits to clinic •Patients should

2018 American Society of Clinical Oncology Guidelines

102. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2017.77.6385 Journal of Clinical (...) Oncology - published online before print February 14, 2018 PMID: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline x Julie R. Brahmer , x Christina Lacchetti , x Bryan J. Schneider , x Michael B. Atkins , x Kelly J. Brassil , x Jeffrey M. Caterino , x Ian Chau , x Marc S. Ernstoff , x Jennifer M. Gardner , x Pamela Ginex , x Sigrun Hallmeyer , x Jennifer Holter Chakrabarty , x

2018 American Society of Clinical Oncology Guidelines

103. Elagolix for Treating Endometriosis

Elagolix for Treating Endometriosis ©Institute for Clinical and Economic Review, 2018 Elagolix for Treating Endometriosis Evidence Report June 15, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Evidence Report– Elagolix for Treating Endometriosis ICER Staff/Consultants University of Colorado Skaggs School of Pharmacy Modeling Group* Steven J. Atlas, MD, MPH Director, Primary Care Research and Quality Improvement Network Massachusetts General Hospital Geri Cramer, BSN (...) , 2018 Page ii Evidence Report– Elagolix for Treating Endometriosis About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more

2018 California Technology Assessment Forum

104. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy

outpatients with FN do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen, should they be considered for hospitalization or continue to be treated on an outpatient basis? METHODS Section: Guideline Update Development Process This systematic review–based guideline product was developed by an Expert Panel with multidisciplinary expertise (Appendix , online only). A patient representative and an ASCO guidelines staff member with health research methodology experience (...) , including frequent clinic visits ○Family member or caregiver at home 24 h/d ○Access to a telephone and transportation 24 h/d ○No history of noncompliance with treatment protocols •The following additional measures are recommended: ○Frequent evaluation for at least 3 days in clinic or at home ○Daily or frequent telephone contact to verify (by home thermometry) that fever resolves ○Monitoring of ANC and platelet count for myeloid reconstitution ○Frequent return visits to clinic •Patients should

2018 Infectious Diseases Society of America

105. Elagolix for Treating Endometriosis

Elagolix for Treating Endometriosis ©Institute for Clinical and Economic Review, 2018 Elagolix for Treating Endometriosis Final Evidence Report August 03, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Final Evidence Report– Elagolix for Treating Endometriosis ICER Staff/Consultants University of Colorado Skaggs School of Pharmacy Modeling Group* Steven J. Atlas, MD, MPH Director, Primary Care Research and Quality Improvement Network Massachusetts General Hospital (...) and Economic Review, 2018 Page ii Final Evidence Report– Elagolix for Treating Endometriosis About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide

2018 California Technology Assessment Forum

106. Location, Location, Location: Treating patients with opioid use disorder in primary care

Location, Location, Location: Treating patients with opioid use disorder in primary care Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) :1-6. Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity. If you are not a member

2018 Tools for Practice

107. Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin

to the ADA, includes as follows: • Plasma blood glucose rather than haemoglobin A1C should be used to diagnose the acute onset of type 1 diabetes in individuals with symptoms of hyperglycaemia. • Screening for type 1 diabetes with a panel of autoantibodies is currently recommended only in the setting of a research trial or in first-degree family members of a proband with type 1 diabetes. • Persistence of two or more autoantibodies predicts clinical diabetes and may serve as an indication for intervention (...) Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 27 July 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment Continuous glucose monitoring (CGM real-time) and flash glucose

2018 EUnetHTA

108. Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia

Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia Decision aid for Dementia: assessment, management and support for people living with dementia and their carers © NICE 2018. All rights reserved. Subject to Notice of rights. Last updated June 2018 Page 1 of 4 Decision aid Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia Information to help people living with dementia, their family members (...) and an increased risk of death. The diagrams on pages 3 and 4 show how likely this is to happen. It is not possible to know in advance what will happen to any individual person. Other things to think about How are antipsychotics taken? Antipsychotics are usually taken as a tablet or a liquid medicine, once or twice a day. Off-label use of antipsychotics Only risperidone (for up to 6 weeks use) and haloperidol have a licence to treat these sorts of problems in people living with dementia. Other antipsychotics

2018 Health Information and Quality Authority

109. Bariatric surgery to treat obesity in individuals under 21 years old

Bariatric surgery to treat obesity in individuals under 21 years old Bariatric surgery to treat obesity in individuals under 21 years old Bariatric surgery to treat obesity in individuals under 21 years old Rodríguez B, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Rodríguez B, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Bariatric surgery to treat obesity in individuals under 21 years old. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 509. 2017 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding

2017 Health Technology Assessment (HTA) Database.

110. Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes

Collaborator: Humana Co.Ltd. Information provided by (Responsible Party): Evidation Health Study Details Study Description Go to Brief Summary: The Diabetes Coaching Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Health Partnership on A1c levels for individuals with uncontrolled Type 2 diabetes. Condition or disease Intervention/treatment (...) educational curriculum combined with proven patient engagement methods. No Intervention: Control Outcome Measures Go to Primary Outcome Measures : A1c [ Time Frame: Baseline and 6 months ] Change in A1c from study baseline to study end for participants Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about

2017 Clinical Trials

111. Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c

: Evidation Health Collaborator: Humana Co.Ltd. Information provided by (Responsible Party): Evidation Health Study Details Study Description Go to Brief Summary: The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes. Condition (...) in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Humana Medicare Advantage member

2017 Clinical Trials

112. The new Secretary of Health and Human Services is a member of a fringe medical organization. Here’s what that means.

The new Secretary of Health and Human Services is a member of a fringe medical organization. Here’s what that means. The new Secretary of Health and Human Services is a member of a fringe medical organization. Here's what that means. | ScienceBlogs Advertisment Search Search Toggle navigation Main navigation The new Secretary of Health and Human Services is a member of a fringe medical organization. Here's what that means. By on November 29, 2016. I’m always hesitant to write about matters (...) Trump picked would have been expected to hold that view. It’s pretty much par for the course for the Republican Party these days. I would have been more surprised if Trump had picked someone who was was relatively neutral on the Affordable Care Act. No, what caught my eye was that I learned that Tom Price is a member of the Association of American Physicians and Surgeons (AAPS), and that told me a lot about him, none of it good. For instance, in 2015 Charles Pierce referred to Price as " ” (Price

2016 Respectful Insolence

113. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy

of guidance 39 6 Appraisal Committee members, guideline representatives and NICE project team 40 Appraisal Committee members 40 NICE project team 42 7 Sources of evidence considered by the Committee 43 Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 451 1 Recommendations (...) family members. The Committee heard from clinical experts that although there have been some advances in this disease area over the last 2 decades through the use of chemotherapies and a targeted agent (for people with HER2 amplification), there was still a need for new active agents, in particular, for those people whose disease had progressed after prior chemotherapy. The Committee concluded that the outlook for people with this disease was poor and that new active treatments offering improved

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

114. Family Building Through Gestational Surrogacy

of information discovered in the course of treatment should be included in the written preconception agreement to provide guidance to the treating physician. Such written agreements are equally important in arrangements that involve gestational carriers who are friends or family members of the intended parent(s) ( ) . Psychosocial Considerations The psychosocial effects of gestational surrogacy on the resulting offspring as well as on the gestational surrogate and her family are important considerations (...) Family Building Through Gestational Surrogacy Family Building Through Gestational Surrogacy - ACOG Menu ▼ Family Building Through Gestational Surrogacy Page Navigation ▼ Number 660, March 2016 (Replaces Committee Opinion No. 397, February 2008) Committee on Ethics This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Ethics. Member contributors included Ginny L. Ryan, MD. While this document reflects the current viewpoint of the College

2016 American College of Obstetricians and Gynecologists

115. Effectiveness of Multidimensional Family Therapy for Reducing Substance Use among Youth

treatment for youth substance use and associated mental health, behavioural and emotional issues that blends principles from family and individual therapies, as well as drug counselling and multiple systems-oriented interventions (Rowe, 2012). It intervenes in each of four major life domains: 1. The adolescent as an individual and as a member of a family and peer network; 2. The parents both as individuals and as caregivers; 3. The family environment and relationships; and 4. Sources of influence (...) . The proportion of youth reporting minimal substance use (no use or use on one occasion of any substance) at 12 months was significantly higher in the MDFT treated group compared to CBT. However, when this Effectiveness of Multidimensional Family Therapy for Reducing Substance Use among Youth Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies Page 4 Pag e 4 outcome was assessed according to baseline substance use problem severity (above [high] or below [low] median number

2016 Canadian Centre on Substance Abuse

116. Faecal transplant effectively treats recurrent or unresponsive Clostridium difficile

studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years. Many studies used reduction in diarrhoea as a marker of effectiveness, rather than C. difficile toxin levels. The randomised trials were assessed as low risk of bias. Including case series, the range of interventions used and variation (...) included seven randomised controlled trials of 428 participants and 30 case series of 1,545 participants. Most studies looked at older adults; some included children and younger people with weakened immune systems. There were no UK based studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years

2019 NIHR Dissemination Centre

117. How do family physicians measure blood pressure in routine clinical practice?: National survey of Canadian family physicians (Full text)

How do family physicians measure blood pressure in routine clinical practice?: National survey of Canadian family physicians To describe the techniques currently used by family physicians in Canada to measure blood pressure (BP) for screening for, diagnosing, and treating hypertension.A Web-based cross-sectional survey distributed by e-mail.Stratified random sample of family physicians in Canada.Family physician members of the College of Family Physicians of Canada with valid e-mail (...) (63.6%, 489 of 769) and AOBP measurement (59.2%, 455 of 769). More than three-quarters (77.8%, 598 of 769) of respondents indicated that ABPM was readily available for their patients.Canadian family physicians exhibit overall high use of electronic devices for BP measurement, However, more efforts are needed to encourage practitioners to follow current Canadian guidelines, which advocate the use of AOBP measurement for hypertension screening, ABPM and home BP measurement for making a diagnosis

2017 Canadian Family Physician PubMed

118. Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

between baseline AR-V7 status and PFS as well as OS and its interaction with treatment. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility (...) Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2018 Clinical Trials

119. Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant

survival [ Time Frame: Up to 1 year ] Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding (...) Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

120. Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Sampling Method: Non-Probability Sample Study Population Patients diagnosed with WHO Grade IV malignant glioma who are approved for and intend (...) Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>